☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
alnylam pharmaceuticals
Alnylam Pharmaceuticals Reports the US FDA’s sNDA Acceptance of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopath...
November 26, 2024
Alnylam Reports the Submission of Regulatory Application of Amvuttra (Vutrisiran) to the EMA Treating ATTR Amyloidosis with Cardio...
October 17, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.